Table 3 Multivariate Cox regression model adjusted for possible predictors estimating cancer-specific and overall survival in 244 patients treated with cyto-reductive nephrectomy for metastatic renal cell carcinoma
Cancer-specific survival | Overall survival | |||||
|---|---|---|---|---|---|---|
HR | 95% CI of HR | p value | HR | 95% CI of HR | p value | |
Age | 1.002 | 0.983–1.021 | 0.865 | 1.003 | 0.986–1.021 | 0.713 |
BMI (kg/m 2) | Reference (< 20) | Reference (< 20) | ||||
20–25 | 0.792 | 0.459–1.369 | 0.404 | 0.805 | 0.485–1.336 | 0.402 |
≥ 25 | 0.443 | 0.202–0.924 | 0.030 | 0.466 | 0.232–0.936 | 0.032 |
Albumin (g/dL) | Reference (< 3.5) | Reference (< 3.5) | ||||
3.5–4.3 | 0.776 | 0.440–1.370 | 0.382 | 0.716 | 0.426–1.204 | 0.208 |
≥ 4.3 | 0.784 | 0.399–1.544 | 0.482 | 0.713 | 0.383–1.328 | 0.287 |
Heng’s criteria | Reference (Low risk) | Reference (Low risk) | ||||
Intermediate risk | 1.095 | 0.623–1.926 | 0.752 | 1.033 | 0.619–1.725 | 0.902 |
High risk | 1.185 | 0.550–2.553 | 0.664 | 1.132 | 0.565–2.270 | 0.727 |
Cholesterol level (cat.) | 2.162 | 1.221–3.829 | 0.008 | 2.013 | 1.206–3.361 | 0.007 |
Age | 1.002 | 0.983–1.021 | 0.830 | 1.003 | 0.986–1.021 | 0.701 |
BMI (kg/m 2) | Reference (< 20) | Reference (< 20) | ||||
20–25 | 0.827 | 0.479–1.430 | 0.497 | 0.857 | 0.517–1.420 | 0.549 |
≥ 25 | 0.462 | 0.214–0.997 | 0.049 | 0.503 | 0.249–1.017 | 0.056 |
Albumin (g/dL) | Reference (< 3.5) | Reference (< 3.5) | ||||
3.5–4.3 | 0.882 | 0.498–1.561 | 0.665 | 0.789 | 0.468–1.327 | 0.371 |
≥ 4.3 | 0.892 | 0.437–1.821 | 0.753 | 0.769 | 0.401–1.473 | 0.428 |
Heng’s criteria | Reference (Low risk) | Reference (Low risk) | ||||
Intermediate | 1.060 | 0.601–1.870 | 0.840 | 1.024 | 0.613–1.712 | 0.927 |
High risk | 1.235 | 0.576–2.649 | 0.588 | 1.193 | 0.596–2.389 | 0.618 |
Cholesterol level (con.) | 0.993 | 0.987–0.999 | 0.032 | 0.995 | 0.989–1.000 | 0.063 |